defactinib

Business news, market intelligence, and global industry analysis.

The Latest

Haleon plc invests £65M in Shanghai oral health plant as China becomes central to its global growth strategy

Haleon (NYSE, LSE: HLN) bets on China’s oral health boom with £65m Shanghai manufacturing facility

Could subcutaneous PD-1 therapy reshape oncology treatment logistics in China?

Cargo theft is rising across North America. Can Eagle Vision Security’s iFM platform stop it before it starts?

The hidden problem with GLP-1 weight loss and Veru Inc.’s bet to fix it (NASDAQ: VERU)

Verastem Oncology’s avutometinib plus defactinib trial in LGSOC published in JCO with robust clinical responses

Verastem Oncology published pivotal Phase 2 RAMP 201 trial results in JCO, showing strong response rates for avutometinib plus defactinib in recurrent LGSOC.

μFR system
αvβ6-integrin
α4β7 integrin
ZYUS Life Sciences
Zyrtec
Zyprexa Zydis
Zynga
Zynext Ventures USA LLC
Zynext Ventures
Zynex

July 13, 2025